JP2004536783A - シグナル−１／シグナル−２二官能性ペプチド阻害剤 - Google Patents

シグナル−１／シグナル−２二官能性ペプチド阻害剤 Download PDF

Info

Publication number
JP2004536783A
JP2004536783A JP2002552127A JP2002552127A JP2004536783A JP 2004536783 A JP2004536783 A JP 2004536783A JP 2002552127 A JP2002552127 A JP 2002552127A JP 2002552127 A JP2002552127 A JP 2002552127A JP 2004536783 A JP2004536783 A JP 2004536783A
Authority
JP
Japan
Prior art keywords
peptide
sequence
signal
amino acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002552127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536783A5 (https=
Inventor
マーレイ，ジョセフ・エス
シャハーン，テルーナ・ジェイ
ヒュー，ヨンボ
Original Assignee
ユニバーシティ・オブ・カンザス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ・オブ・カンザス filed Critical ユニバーシティ・オブ・カンザス
Publication of JP2004536783A publication Critical patent/JP2004536783A/ja
Publication of JP2004536783A5 publication Critical patent/JP2004536783A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002552127A 2000-12-18 2001-12-17 シグナル−１／シグナル−２二官能性ペプチド阻害剤 Pending JP2004536783A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/739,466 US7786257B2 (en) 2000-12-18 2000-12-18 Signal-1/signal-2 bifunctional peptide inhibitors
PCT/US2001/048632 WO2002050250A2 (en) 2000-12-18 2001-12-17 Signal-1/signal-2 bifunctional peptide inhibitors

Publications (2)

Publication Number Publication Date
JP2004536783A true JP2004536783A (ja) 2004-12-09
JP2004536783A5 JP2004536783A5 (https=) 2005-06-09

Family

ID=24972431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002552127A Pending JP2004536783A (ja) 2000-12-18 2001-12-17 シグナル−１／シグナル−２二官能性ペプチド阻害剤

Country Status (8)

Country Link
US (1) US7786257B2 (https=)
EP (2) EP1404362B1 (https=)
JP (1) JP2004536783A (https=)
AT (1) ATE400293T1 (https=)
AU (1) AU2002230911A1 (https=)
CA (1) CA2432767A1 (https=)
DE (1) DE60134791D1 (https=)
WO (1) WO2002050250A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061490A (ja) * 2011-10-18 2017-03-30 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ シリンガレシノールを含むｓｉｒｔ−１活性化剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
EP2083715B1 (en) * 2006-11-30 2013-03-13 Cook Medical Technologies LLC Removable handle for medical device
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
NZ583362A (en) 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
KR101557173B1 (ko) * 2007-10-25 2015-10-05 더 스크립스 리서치 인스티튜트 박테리아에서의 쿼럼 센싱의 항체 매개성 파괴
DE102009040716B4 (de) * 2009-09-10 2011-07-14 Miltenyi Biotec GmbH, 51429 Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen
EP2585108A4 (en) 2010-06-24 2016-04-13 Univ Kansas CONJUGATES WITH AN N-OXIM BINDING AND ASSOCIATED METHODS
EP2736536A4 (en) 2011-07-27 2015-03-11 Univ Kansas TEMPLATE ISLAND CELLS AND SMALL ISLAND CELL PATTERNS FOR THE TREATMENT OF DIABETES
US11919939B2 (en) * 2017-05-23 2024-03-05 Université De Genève Beta-2-glycoprotein 1 derived peptide and use thereof for treating antiphospholipid syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE59310308D1 (de) * 1992-06-11 2002-11-21 Merck Patent Gmbh Verfahren und Mittel zum Nachweis von Listerien
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69840326D1 (de) 1997-03-27 2009-01-22 Csl Ltd Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2001026608A2 (en) * 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061490A (ja) * 2011-10-18 2017-03-30 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ シリンガレシノールを含むｓｉｒｔ−１活性化剤

Also Published As

Publication number Publication date
AU2002230911A1 (en) 2002-07-01
US20050107585A1 (en) 2005-05-19
EP1404362A4 (en) 2005-06-01
EP1932539A3 (en) 2008-10-29
WO2002050250A3 (en) 2004-01-08
EP1404362A2 (en) 2004-04-07
ATE400293T1 (de) 2008-07-15
CA2432767A1 (en) 2002-06-27
EP1932539A2 (en) 2008-06-18
US7786257B2 (en) 2010-08-31
WO2002050250A2 (en) 2002-06-27
DE60134791D1 (de) 2008-08-21
EP1404362B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
US8518697B2 (en) Single chain trimers and uses therefor
ES2278390T3 (es) Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
US10035857B2 (en) Regulatory T cell mediator proteins and uses thereof
US6984625B2 (en) Methods and compositions for modulating autoimmunity
US8349320B2 (en) Compositions and methods for modulating responses mediated or associated with BTLA activity
JP2001508430A (ja) 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法
HU228477B1 (en) Pd-1, a receptor for b7-4, and uses therefor
Lunde et al. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies
US20230015969A1 (en) Regulatory t cell mediator proteins and uses thereof
EP1404362B1 (en) Signal-1/signal-2 bifunctional peptide inhibitors
US11701387B2 (en) Chimeric antigen receptor specific for BDCA2 antigen
TW202426486A (zh) 使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
WO2016131911A1 (en) Methods for the treatment and diagnosis of type 1 diabetes
WO2001026679A2 (en) T-cells and molecules involved in immune regulation
Miloro Deciphering the role of the death receptor Fas/CD95 in T cell co-stimulation
Tucker The Divergent Role of Co-receptors and Cytokines in the Immune Response to Cancer and Self
Cobbold T cell tolerance in transplantation: possibilities for therapeutic intervention
Jangalwe Regulation of Alloreactive CD8 T Cell Responses by Costimulation and Inflammation
Zajac Antiviral cell-mediated immune responses in beta-2-microglobulin deficient mice
Su Mechanisms of peptide-IgG gene-transferred tolerance induction: Antigen presentation by tolerogenic B cells and the role of IgG heavy chain
Sutherland BAFF regulation of peripheral T cell responses
Telander Clonal anergy: its biochemical basis and functional consequences
AU2005295918A1 (en) Methods and materials for the inhibition of transplant rejection
Chen et al. Specific tolerance induction of allo-Kb-skin grafts by FK506 in the CD8-depleted H-2k recipients required low amounts of Kb-antigen
Teng Analysis of the mechanism (s) of immunological tolerance to a physiological soluble antigen in transgenic mice

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090311